Samsung Biologics
Samsung Biologics is a publicly-traded biotechnology company that works in contract development and manufacturing. The company is headquartered in Songdo, Incheon, South Korea as the biotech division of Samsung. It was founded in 2011. From 2011 to 2018, Samsung Biologics built three manufacturing plants with a capacity of more than 360,000 liters, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.
In 2012, it established Samsung Bioepis, a biosimilar medicine producer, with Biogen. The company has partnered with GlaxoSmithKline for biologics products, UCB on the production of a clinical trial to treat supranuclear palsy and Vir Biotechnology and CytoDyn on the manufacturing of monoclonal antibodies during the COVID-19 pandemic. In November 2019, Samsung Biologics became the first contract manufacturing organization to obtain ISO 27001 certification. The company also obtained an ISO 22301 certification in May 2020, the first in the Korean biopharma industry.
